KRAS and cancer: Our findings that NOP56 KD cells are exposed to higher levels of metabolic ROS and display a greater dependency on UPR-activated mTOR signaling suggest a synthetic lethal vulnerability in KRAS-mutant cancer (Figs. 1, 2, 3).